An open-label, dose-finding, phase Ib study to assess the safety, tolerability of nesuparib (JPI-547), a dual inhibitor of PARP/TNKS, in combination with modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine-nab-paclitaxel (GemAbraxane) in patients with locally advanced and metastatic pancreatic cancer.

Authors: Do-Youn Oh, Jin Won Kim, Joon Oh Park, Hye Jin Choi, Jeesun Yoon, Minsu Kang, Jung Yong Hong, Choong-kun Lee, Hyesoo Kwon, Eunji Kim, Hyunju Cha, Jun Kim, John Kim

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4227

Source: Full article

---

Abstract

TPS4227